Crestor Patent Invalidity Evidence Uncovered By Article One Partners...(nowledge and referral networks of our Ad...),Health

Date:7/1/2009

nowledge and referral networks of our Advisors, this evidence known as prior art can be discovered. Prior art may come from published content anywhere in the world and in any language, including: previous patents; news or academic publications; non-digitized documents such as textbooks; or any public document provided to others, including conference or academic papers and business materials. Article One and its Clients analyze the prior art to determine whether it can show patents to be legitimized or invalid.

If Article One or its Clients determine that the submissions of its Advisors can show patents to be invalid, Advisors earn up to $50,000. Advisors who actively build the community also earn premium compensation in a Profit Sharing Plan, distributing approximately five percent (5%) of Article One's net annual profit. The result is a highly-rewarded community providing a second, citizen's review of U.S. patents to justify monopoly pricing for true innovation and energize U.S. patent reform. To learn more about Article One Partners, or to become a member of our community, please visit www.ArticleOnePartners.com .

Article One Partners and AOP are service marks of Article One Partners, LLC. All other product and company names are the trademarks and property of their respective owners.

(C) 2009. Article One Partners, LLC. All rights reserved.

'/>"/>

SOURCE Article One Partners, LLC Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine news :

1. CRESTOR(R) Now Indicated to Slow the Progression of Atherosclerosis in Patients With Elevated Cholesterol
2. Analyst Available to Comment on New JUPITER Study That Shows AstraZenecas Crestor Significantly Reduces CV Risk
3. CRESTOR Cuts Risk of Stroke by Nearly Half in JUPITER Study
4. As a Result of the Jupiter Trial, 65 Percent of Surveyed MCO Pharmacy Directors Will Reimburse Crestor for Patients with Elevated hsCRP
5. Video: CRESTOR(R) Reduced Risk of Blood Clots in the Veins
6. Patent Reform Legislation Threatens Americas Leadership in Medical Technology Innovation
7. Spectranetics to Appeal Decision in Patent Litigation
8. Patent Expiries of Proscar and Flomax/Harnal Will Cause a Significant Decline in Near-Term Sales of Benign Prostatic Hyperplasia Drugs
9. Actavis Confirms its Patent Challenge of Kings Avinza(R)
10. PartsSource Awarded US Patent for PartsFinder(TM) Application
11. Barr Confirms Patent Challenge of UROXATRAL(R)